Ultragenyx Pharmaceutical stock moves after performance data

Ultragenyx Pharmaceutical (RARE) drew fresh attention after its stock fell about 4.6% in the latest session, extending a roughly 7.8% decline over the past month and contrasting with a gain over the past 3 months.

The recent 1 month share price return of down 7.8%, together with a 1 year total shareholder return decline of 36.8%, suggests momentum has been fading, even though the 3 month share price return is slightly positive.

If you are weighing Ultragenyx Pharmaceutical against other opportunities in healthcare, this is a good moment to see what else is moving with 40 healthcare AI stocks

With the stock down sharply over 1 and 5 years, while revenue and net income growth figures are reported as positive and the share price sits far below analyst targets, you have to ask: is Ultragenyx undervalued, or is the market already pricing in future growth?

Most Popular Narrative: 56.4% Undervalued

Against Ultragenyx Pharmaceutical's last close at $22.85, the most followed narrative points to a fair value of $52.45, framing the recent share price slide in a very different light.

The accelerating global identification and diagnosis of rare diseases, supported by advancements in genomics and genetic testing, are expanding the addressable patient pool for Ultragenyx's existing and future therapies, which should drive sustained long-term revenue growth. Healthcare payers and regulatory agencies are increasingly recognizing the value of orphan drugs, as evidenced by faster development timelines and ongoing pricing or reimbursement wins in regions like Latin America and EMEA, supporting robust revenue streams and pricing power over the next several years.

Curious what assumptions sit behind that fair value gap? Revenue growth, margin expansion and a rich future earnings multiple all play a part. The full narrative lays out how these pieces fit together and what would need to happen in the business for $52.45 to make sense.

Result: Fair Value of $52.45 (UNDERVALUED)

However, several things could break this story, including continued heavy losses that strain cash, as well as any further regulatory setbacks for key gene therapy programs.

Next Steps

With sentiment clearly mixed, this is the moment to look through the numbers yourself and decide where you stand. Start with 2 key rewards and 3 important warning signs.

Looking for more investment ideas?

If Ultragenyx has your attention, do not stop here. Broaden your watchlist with fresh ideas that match what you care about in a stock.

• Spot potential bargains early by reviewing companies highlighted in the 47 high quality undervalued stocks.
• Prioritize resilience by scanning stocks in the 62 resilient stocks with low risk scores.
• Hunt for future standouts before the crowd by checking the screener containing 22 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.